News Progressive MS Clinical Trial of Rituximab Stopped After Drug Fails to Show Effectiveness Progressive MS Clinical Trial of Rituximab Stopped After Drug Fails to Show Effectiveness by Margarida Azevedo, MSc | March 7, 2016 Share this article: Share article via email Copy article link Researchers at the National Institutes of Health (NIH)Ā announced that a small clinical trial of a progressive multiple sclerosis (MS) treatment was stopped early due to poor results. The trial was evaluating the drug rituximab for its efficacy in depleting harmful immune cells and decreasing nerve damage in these MS patients. The results were published in an article, titled āInsufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis,ā in the journal The Annals of Clinical and Translational Neurology. According to theĀ International Progressive MS Alliance (PMSA), as many as 80 percent of people with MS may develop a type of progressive form of the disease. Unlike relapsing-remitting MS (RRMS), the most common type of the disease, there are no effective therapies for progressive MS. The lack of efficacy of RRMS-targeted drugs in progressive MS patients isĀ attributed to the fact that inflammation in progressive MS occurs in compartments of the brain and spinal cord that these drugs cannotĀ access due to the selectivity of the blood-brain barrier. Researchers launched a small study investigating the potential of rituximab to treatĀ progressive MS. Rituximab, which is used to treat rheumatoid arthritis and certain cancers, depletes B cells, immune cells that are thought to play a role in the exacerbated inflammation damage observed in MS. The clinical trial, āDouble Blind Combination Rituximab byĀ IntraVenous andIntraThecAl injection versus placebo in patients withĀ Low-InflammatoryĀ SEcondary progressive MSā (RIVITaLISe; NCT01212094), aimed to answer two questions: Can rituximab efficiently deplete central nervous system (CNS) B cells? and, if so, Does this lead to inhibition of CNS inflammation and slowing of CNS tissue destruction? The study enrolled 27 people with secondary-progressive MS, who were either assigned to the rituximab group or the placebo group. Interim analyses of ongoing results, however, showed that B cells in the spinal fluid were not being depleted at a significant rate by the drug, which was interpreted as rituximab’s lack of efficacy atĀ entering the CNS. Moreover, researchers found that the levels of axonal damage marker, neurofilament light chain, did not change in response to treatment. In light of such results, the clinical trial was terminated. Future plans include the ongoing studies of other treatments for progressive MS.Ā On aĀ positive note, the drug ocrelizumab was found to achieve positive results in primary-progressive MS and relapsing MS in 2015. Print This Page About the Author Margarida Azevedo, MSc Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior TĆ©cnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies. Tags clinical trial, progressive MS, rituximab
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8